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Background: Populations of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa undergo extensive diversiﬁcation in the cystic
ﬁbrosis (CF) lung during long-term chronic infections.
Methods: We analyzed sets of 40 isolates from the sputa of ﬁve CF patients, each chronically infected with a different non-LES strain of
P. aeruginosa. For each sample (two per patient), diversity was assessed by characterizing nine phenotypic traits.
Results: All P. aeruginosa populations were highly diverse, with the majority of phenotypic variation being due to within-sample diversity.
Conclusions: Maintenance of diverse populations in the CF lung is a common feature of P. aeruginosa infections.
© 2013 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. Open access under CC BY license.Keywords: Pseudomonas aeruginosa; Cystic ﬁbrosis; Population biology1. Introduction
During chronic lung infections of cystic fibrosis (CF) patients
Pseudomonas aeruginosa adapts by accumulating mutations
associated with phenotypic adaptations, leading to populations of
P. aeruginosa composed of multiple clones with differing anti-
microbial susceptibility profiles [1,2]. Previously [3], we analyzed
P. aeruginosa sputum populations from ten CF patients each
infected with an important transmissible strain, the Liverpool Ep-
idemic Strain (LES) [4,5], and showed that LES populations were
highly diverse and dynamic during CF infections [3].
Studies using sequential isolates have demonstrated the accu-
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patients in Denmark, suggested that after the accumulation of
mutations during the early stages of infection, a homogeneous
population of DK2 emerged [10], appearing to contradict our
observations.
Here, we examined the diversity of P. aeruginosa popula-
tions in five adult CF patients each chronically infected with a
different non-LES strain of P. aeruginosa. To test whether
extensive diversification is a feature unique to the LES, or
common to P. aeruginosa infections of CF patients in general,
we compared LES and non-LES populations from matched
chronically infected adult CF patients.2. Materials and methods
2.1. Patients and samples
Sputum samples were collected for routine diagnostic purposes
from adult CF patients (CF20–CF24; Table 1) chronically infected
(N5 years) with different non-LES strains of P. aeruginosa inCystic Fibrosis Society. Open access under CC BY license.
Table 1
Patient details and phenotypic characteristic exhibited by sputum isolates from patients chronically infected with P. aeruginosa.
Patient Patient characteristics Total nSub a Mutations
(%)
Antibiotic resistance
(%)
Colony morphology type
(%)
Sex Age (y) FEV1 (%) BMI n HM Aux TOB COL CEF CIP MER TAZ GM GNMS Mtr MWO StNMS RM
Non-LES
CF20 M 26 41 23 80 22 25 95 61 0 75 42 20 17.5 2 48 0 2 48 0
CF21 M 30 43 15 80 15 61 10 0 0 25 50 20 0 0 47 0 3 50 0
CF22 M 21 38 16 80 8 0 100 0 0 2 5 0 0 2 76 0 0 22 0
CF23 M 21 38 21 80 23 0 71 2 0 31 21 34 24 0 0 0 25 75 0
CF24 M 22 54 20 80 16 22 0 0 0 61 90 46 0 0 76 0 24 0 0
All (mean) 24 43 19 400 16.8 22 55 13 0 39 42 24 8 1 49 0 11 39 0
LES
CF3 F 22 66 28 80 19 2 38 61 0 70 4 60 2 42 0 2 0 56 0
CF4 M 33 45 19 80 31 8 12 12 0 10 16 2 2 4 36 0 34 24 2
CF7 F 24 40 17 80 19 2 18 35 0 35 14 0 0 0 0 8 52 42 0
CF8 F 27 39 18 80 16 5 52 8 0 55 12 94 48 72 14 0 12 0 2
CF10 F 24 40 17 80 25 12 4 82 0 66 8 66 18 0 48 0 4 48 0
All (mean) 26 46 20 400 21.6 6 25 40 0 47 11 44 14 24 20 2 20 34 1
Abbreviations: FEV1, forced expiratory volume in 1 s; BMI, body mass index; HM, hypermutable phenotype; Aux, auxotrophy; TOB, tobramycin; COL, colistin; CEF,
ceftazidime; CIP, ciprofloxacin; MER, meropenem; TAZ, tazobactam/pipericillin; GM, green mucoid; GNMS, green non-mucoid smooth; Mtr, mucoid transparent;
MWO, mucoid white opaque; RM, red mucoid; StNMS, straw coloured non-mucoid smooth.
a nSub indicates the total number of different sub-types for each set of 80 isolates.
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[11] and identified according to the hexadecimal code generated by
this method as genotypes 2F82 (CF21), 2C1A (CF22; Midlands 1
strain [12]), 0F1A (CF23), C80A (CF24) and AF9A (CF25).
Samples taken during periods of exacerbation (defined as
previously [13]) were sub-divided into two categories: beginning
of an exacerbation (acute 1), before intravenous antibiotic
treatment had commenced; typically 3–7 days after admission
(acute 2). For each patient included in this study, one acute 1 and
one acute 2 sample was used. The five patients chronically infected
with non-LES strains were matched with five LES-infected
patients (Table 1). Comparison data for LES-infected patients
was taken from a previous study [3]. As far as possible, patients
with similar age, lung function (FEV1) and BMI were selected.
This study was approved by the Local Research Ethics Committee
(REC reference 08/H1006/47).
2.2. Microbiology and phenotypic/genotypic tests
P. aeruginosawas isolated from sputum samples as described
previously [2]. From each sputum sample, 40 single colonies
were analyzed, ensuring that each different colony morphology
type was represented in proportion to their abundance. Isolates,
confirmed as P. aeruginosa but non-LES using PCR assays
[12,14], were analyzed for nine phenotypic traits: colony
morphology, auxotrophy, hypermutability [15], and susceptibil-
ity to six antimicrobial agents (tobramycin, colistin, ceftazidime,
ciprofloxacin, meropenem and tazobactam/pipericillin) [3].
2.3. Statistical analyses
In order to estimate the population differentiation between
patients, between samples within patients and between isolateswithin samples, we performed hierarchical analysis of variance
using the ade4 package in R (r-project.org). We define a
sub-type as a specific combination of trait values, and the
phenotypic distance between a pair of sub-types as the number
of traits that differed between them. Sub-type diversity was
calculated as the probability of two randomly picked isolates
being the same sub-type based on the sub-type frequencies
within a sample. Sub-type sharing between a pair of samples
was calculated as the probability of a randomly picked isolate
from each sample sharing the same sub-type. This sub-type
sharing probability was normalised using a logit transform (log
[p / (1 − p)]).3. Results
3.1. Overall P. aeruginosa phenotypic diversity
High phenotypic diversity was apparent in the P. aeruginosa
populations from each of the chronically infected CF patients.
Based on the nine phenotypic traits analyzed, 400 isolates
taken from 10 sputum samples from non-LES-infected patients
comprised a total of 75 distinct phenotypic sub-types. The
number of sub-types present within each patient is shown
in Table 1, along with the frequency of each of the charac-
teristics measured. When the data from LES-infected and
non-LES-infected patients were analyzed together, there were
152 sub-types of P. aeruginosa present in total, of which 97
were found only in LES-infected patients, 76 were found
only in non-LES-infected patients, and 21were shared between
the two groups (see Supplementary Fig. 1). There was a mean
of 10 sub-types per set of 40 isolates for samples from
non-LES-infected patients, compared to 10 for samples from
LES-infected patients.
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Hierarchical analysis of variance was performed on LES
and non-LES groups separately to estimate the proportion of
phenotypic variation attributable to (i) variation among patients,
(ii) variation among samples within patients, and (iii) variation
among isolates within samples. In both groups, the greatest
contribution to overall diversity was due to phenotypic diversity
between isolates within samples (LES-infected patients, 83%;
non-LES infected patients, 81%). Overall, the LES and non-LES
infections exhibited equivalent levels of diversity within a single
sputum sample (Fig. 1a) and an equivalent degree of correlation
between different sputum samples taken from the same patient
(Fig. 1b).0.
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Fig. 1. Comparisons between non-LES and LES samples. (a) Diversity within
LES and non-LES samples is calculated from the probability of two isolates
within a sample being of the same sub-type (pshare). Circles and triangles
represent samples from the beginning and end of an exacerbation, respectively.
No statistically differences in diversity were observed, either between non-LES
and LES samples or between samples from the beginning versus end of an
exacerbation. (b) Similarity between pairs of samples taken from the same
patient. Similarity is calculated from the probability of two isolates from
different samples being of the same haplotype (pshare). Circles represent pairs of
samples taken at the beginning and end of an exacerbation and, hence, less than
one month apart. Triangles represent pairs of samples taken at the beginning of
separate exacerbations more than two months apart. Dotted lines indicate the
mean level of similarity between samples from different patients within either
the non-LES or the LES groups.3.3. Frequency of phenotypic traits
There were differences between the groups (non-LES-infected
versus LES-infected patients) with respect to some of the
phenotypes tested. For example, there was a far greater range in
prevalence of isolates exhibiting the hypermutability pheno-
type amongst the non-LES samples [Non-LES (0–61%), LES
(2–12%)]. Susceptibilities to commonly used antibiotics varied
considerably within patient samples, with the exception of colistin
(Table 1).4. Discussion
Previous studies, tending to focus on small numbers of
sequential isolates [6–8], have concluded that P. aeruginosa
adapts in specific ways, including loss of virulence. Yet, it has
been demonstrated that concurrent pairs of isolates can also
vary considerably from each other [16], and we have shown
previously that some strains exhibit dynamic turnover of
sub-types exhibiting different phenotypic and genotypic
characteristics [3]. It has been suggested that some strains
reach an evolutionary plateau, characterized by low phenotyp-
ic variations [10], leading us to wonder whether the extensive
diversification seen with chronic LES infections may be a
particular feature of this strain. Here we analyzed samples
from multiple adult CF patients infected with non-LES
P. aeruginosa strains and compared them with equivalent
samples from LES-infected patients. Our observations suggest
that the extensive diversity reported previously is a widespread
feature of P. aeruginosa populations in the lungs of CF patients
who have been chronically infected for long periods. For both
groups (LES and non-LES), the greatest contribution to the
diversity in sub-types observed was within individual sputum
samples, rather than because of variation between patients,
even though the non-LES group patients were each infected
with a different strain.
The wider range of frequencies of some of the phenotypic traits
measured between the LES-infected and the non-LES-infected
groups is likely to be due to strain-specific variations in the
non-LES group. Hence, although the extent of diversity was
not different between the two groups, the actual phenotypes
contributing to the variations differed. It should be noted
that the isolates were not randomly selected. However, the
selection criteria were the same for each sample.
This study provides further evidence that the CF lung, which
constitutes a spatially heterogeneous environment with multiple
discrete ecological niches, is able to sustain multiple divergent
sub-types of P. aeruginosa simultaneously, and that this is a
common feature of these kinds of infections.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jcf.2013.04.003.Acknowledgements
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